The stock has demonstrated a strong overall uptrend over the past six months, with the price rising from approximately $75.31 in early October 2025 to $89.39 as of March 30, 2026, representing a gain of about 18.7%. This performance significantly outpaced the broader market, as indicated by a 6-month relative strength of 24.27. In the short term, the stock has experienced volatility, declining 10.24% over the past month but still posting an 8.13% gain over the last three months. The current price of $89.39 sits near the middle of its 52-week range of $49.00 to $106.98, approximately 16.4% below the yearly high. The 1-month relative strength of -2.37 suggests recent underperformance versus the market.

Revenue and profitability have shown significant volatility on a quarterly basis. The most recent Q4 2025 revenue of $1.45 billion grew 31.25% year-over-year, with net income of $201.6 million, a sharp recovery from a net loss of $34.3 million in Q4 2024. However, this follows a substantial net loss of $855.8 million in Q2 2025, indicating inconsistent earnings. The company's financial health is a concern, with a very high debt-to-equity ratio of 6.32. Positively, the trailing twelve-month free cash flow is strong at approximately $829.9 million, and the current ratio of 1.38 suggests adequate short-term liquidity. Operational efficiency metrics are mixed, with a negative Return on Equity (ROE) of -0.60, but a positive Return on Assets (ROA) of 0.11 for the latest period.